A First-In-Human Study of LY3839840 in Healthy Participants
Completed · Phase 1 · NCT06153355
Conditions: Healthy
At a glance
- Research payments reported, 2025
- $3.9M
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 140
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3839840 (drug), Placebo (drug), Midazolam (drug)
- Dates
- Started 2023-12-04; completion 2025-05-22
- Results posted
- Not yet
The main purpose of this first-in-human study to investigate the safety of LY3839840 in single and multiple doses, and how it's processed in the body when given in different amounts.
From ClinicalTrials.gov, last updated 2025-06-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $3.9M in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Amina Z. Haggag, M.D. Family Medicine · Northridge, CA
- Kathleen M. Doisy, MD Pediatrics · Columbia, MO
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Fortrea Clinical Research Unit Inc $3.7M
- Anaheim Clinical Trials LLC $161,084
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.